3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
71
Phase 2
36
Phase 3
20
Phase 1/2
19
Phase NA
3
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Breast Neoplasms
10
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Thoracic Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Patient Acceptance of Health Care
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Lung Diseases
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Large Cell
1
Cancer Therapy-related Cardiovascular Toxicity
1
Breast Neoplasm Female
1
Interventions
Dexamethasone
8
Oxycodone
6
Epoetin Alfa
5
Propofol
4
Palonosetron
4
Meropenem
4
Zoledronic Acid
3
Vancomycin
3
Sevoflurane
3
Ondansetron
3
Naloxone
3
Everolimus
3
Ciprofloxacin
3
Cholecalciferol
3
Ceftazidime
3
Cefepime
3
Calcium Dobesilate
3
Bevacizumab
3
Aspirin
3
Aprepitant
3
peginterferon alfa-2a
2
edoxaban
2
apixaban
2
apatinib
2
Vitamin B 12
2
Vincristine
2
Tobacco Use Cessation Devices
2
Teicoplanin
2
Tablets
2
Surgical Procedures, Operative
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Neoplasms
×
Paclitaxel
×
Clear all
NCT00606515
2009-02-10
LPS-PK-H
Shandong Luye Pharmaceutical Co., Ltd.
Phase 4
Completed
16 enrolled